Latest Healthcare News

Ingenia Communities Group (ASX: INA) reported an 18% rise in FY26 EBIT to $193.4 million, beating guidance, while underlying EPS grew 16% to 35.8 cents. The group also extended its land lease development pipeline to 8,800 sites, underpinning future growth.

Embelton Limited has reported a solid 20.4% increase in revenue and a 34.7% jump in profit after tax for FY2026, underpinned by a strategic pivot away from residential construction towards infrastructure and social sectors. The company held its dividend steady amid improving cash flow and reduced borrowings.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

Oakridge International Limited has reversed its fortunes with a 42% revenue increase to $3.45 million and a return to profitability in FY2026, driven by healthcare technology sales and strategic platform enhancements.

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.

EMVision Medical Devices has made significant strides in its emu™ bedside scanner pivotal trial and First Responder program, boosting FY26 revenue by 57% while trimming its net loss by 15%.

WAM Research’s FY2026 investment portfolio dropped 18%, dragging the company to a $28 million net loss. Despite underperformance, the LIC sustains its 10 cents per share dividend, backed by strong reserves and franking credits.

Regis Healthcare reported a robust FY26 with revenue hitting $1.35 billion, underpinned by strong occupancy and strategic acquisitions. The company is investing heavily in growth and digital transformation while navigating sector reforms and climate risks.

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.

nib Group reported a 6.2% revenue increase to $3.8 billion and a 9.1% rise in underlying operating profit to $260.9 million for FY26, despite a 5.9% net profit dip. The company achieved maiden profitability in Health Services and declared a fully franked 21c dividend including a 5c special, supported by ongoing Travel insurance divestments.